Reporting and handling missing outcome data in mental health: A systematic review of cochrane systematic reviews and meta-analyses

Research Synthesis Methods

Volumn 6, Issue 2, 2015, Pages 175-187

  Spineli, Loukia M ^a   Pandis, Nikolaos ^b,c   Salanti, Georgia ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF BERN   (Switzerland)

^c Private Practice in Pediatrics   (Greece)

Author keywords

Intention to treat analysis; Last observation carried forward; Missing outcome data; Psychiatric trials; Systematic reviews

Indexed keywords

COMPUTER SIMULATION; EVIDENCE BASED MEDICINE; HUMAN; LITERATURE; MENTAL DISORDERS; META ANALYSIS; META ANALYSIS (TOPIC); METHODOLOGY; OUTCOME ASSESSMENT; PREVALENCE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

COMPUTER SIMULATION; DATA INTERPRETATION, STATISTICAL; EVIDENCE-BASED MEDICINE; HUMANS; MENTAL DISORDERS; META-ANALYSIS AS TOPIC; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE); PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; REVIEW LITERATURE AS TOPIC; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84929945015     PISSN: None     EISSN: 17592887     Source Type: Journal    
DOI: 10.1002/jrsm.1131     Document Type: Article

References (40)

1. Abraha I, Montedori A. 2010. Modied intention to treat reporting in randomised controlled trials: systematic review. BMJ 340: c2697.
2. Akl EA, Briel M, You JJ, Sun X, Johnston BC, Busse JW, Mulla S, Lamontagne F, Bassler D, Vera C, Alshurafa M, Katsios CM, Zhou Q, Cukierman-Yaffe T, Gangji A, Mills EJ, Walter SD, Cook DJ, Schünemann HJ, Altman DG, Guyatt GH. 2012. Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. BMJ 344: e2809.
3. Akl EA, Johnston BC, Alonso-Coello P, Neumann I, EbrahimS, BrielM, Cook DJ, Guyatt GH. 2013. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewer. PloS One 8(2): e57132.
4. Alshurafa M, Briel M, Akl EA, Haines T, Moayyedi P, Gentles SJ, Rios L, Tran C, Bhatnagar N, Lamontagne F, Walter SD, Guyatt GH. 2012. Inconsistent denitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature. PloS One 7(11): e49163.
5. Bell ML, Kenward MG, Fairclough DL, Horton NJ. 2013. Differential dropout and bias in randomised controlled trials: when it matters and when it may not. BMJ 346: e8668.
6. Carpenter JR, Kenward MG. 2008. Missing data in randomized controlled trials: a practical guide. National Institute for Health Research: Birmingham.
7. Cipriani A1, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, McGuire H, Barbui C. 2010. Sertraline versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews (2):CD006117.doi: 10.1002/14651858.CD006117.pub4.
8. Dumville JC, Torgerson DJ, Hewitt CE. 2006. Reporting attrition in randomised controlled trials. BMJ 332(7547): 969-971.
9. European Medicines Evaluation Agency. 2009. Guideline on Missing Data in Conrmatory Clinical Trials. Committee for Medical Products for Human Use.
10. Furukawa TA, Streiner D, Young LT. 2001. Antidepressants plus benzodiazepines for major depression. Cochrane Database of Systematic Reviews (3): CD001026.
11. Gamble C, Hollis S. 2005. Uncertainty method improved on best-worst case analysis in a binary meta-analysis. Journal of Clinical Epidemiology 58(6): 579-588.
12. Guaiana G, Barbui C, Cipriani A. 2010. Hydroxyzine for generalised anxiety disorder. Cochrane Database of Systematic Reviews (12): CD006815. doi: 10.1002/14651858.CD006815.pub2.
13. Hamer RM, Simpson PM. 2009. Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. The American Journal of Psychiatry 166(6): 639-641.
14. Hammad T. Relationship between psychotropic drugs and pediatric suicidality. 2004. Available at: http://www.fda. gov/ohrms/dockets/ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf [Accessed: March 2014]. FDA, pp. 1-131.
15. Haukoos JS, Newgard CD. 2007. Advanced statistics: missing data in clinical research--part 1: an introduction and conceptual framework. Academic Emergency Medicine 14(7): 662-668.
16. Helfand M, Berg A, Flum D, Gabriel S, Normand SL. 2012. 'Our questions, our decisions: Standards for patient-centered outcomes research'. Public comment draft report of the Patient-Centered Outcomes Research Institute (PCORI) Methodology Committee. Presented on 23 July, and revised thereafter.
17. Heo M, Papademetriou E, Meyers BS. 2009. Design characteristics that inuence attrition in geriatric antidepressant trials: meta-analysis. International Journal of Geriatric Psychiatry 24(9): 990-1001.
18. Hewitt CE, Kumaravel B, Dumville JC, Torgerson DJ on behalf of the Trial attrition study group. 2010. Assessing the impact of attrition in randomized controlled trials. Journal of Clinical Epidemiology 63(11): 1264-1270.
19. Higgins JP, White IR, Wood AM. 2008. Imputation methods for missing outcome data in meta-analysis of clinical trials. Clinical Trials 5(3): 225-239.
20. Higgins JP, Deeks JJ, Altman DG, on behalf of the Cochrane Statistical Methods Group. 2009. General principles for dealing with missing data. Cochrane handbook. Available at: http://www.cochrane-handbook.org.
21. Higgins JP, Altman DG, Sterne JAC. 2011. Assessing risk of bias in included studies. In Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011), Higgins JP, Green S (eds). The Cochrane Collaboration.
22. Hollis S, Campbell F. 1999. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 319(7211): 670-674.
23. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 1998. Statistical principles for clinical trials. Step 5: Note for guidance on statistical principles for clinical trials. In International Conference on Harmonization (ICH) Topic E9. Published in the Federal Register, p. 23.
24. Joshi M, Royuela A, Zamora J. 2013. Proper analysis in clinical trials: how to report and adjust for missing outcome data. BJOG 120(8): 915-919.
25. Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW. 2005. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Archives of General Psychiatry 62(12):1305-1312.
26. Khan A, Warner HA, Brown WA. 2000. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Archives of General Psychiatry 57(4): 311-317.
27. Lane P. 2008. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharmaceutical Statistics 7(2): 93-106.
28. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. 2006. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 59(11): 1001-1005.
29. Leucht S, Engel RR, Bauml J, Davis JM. 2007. Is the superior efcacy of new generation antipsychotics an artifact of LOCF? Schizophrenia Bulletin 33(1): 183-191.
30. Liu-Seifert H, Adams DH, Kinon BJ. 2005. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Medicine 3:21-30.
31. Mavridis D,White I, Higgins J, Cipriani A, Salanti G. 2014. Allowing for uncertainty due to missing continuous outcome data in pairwise and network meta-analysis. Statistics in Medicine. doi: 10.1002/sim.6365. [Epub ahead of print].
32. National Research Council, Panel on Handling Missing Data in Clinical Trials. 2010. 'Front Matter'. The Prevention and Treatment of Missing Data in Clinical Trials. The National Academies Press: Washington, DC.
33. Nemeroff CB. 2003. Improving antidepressant adherence. Journal of Clinical Psychiatry 64(Suppl. 18): 25-30.
34. Rabinowitz J, Davidov O. 2008a. A composite approach that includes dropout rates when analyzing efcacy data in clinical trials of antipsychotic medications. Schizophrenia Bulletin 34(6): 1145-1150.
35. Rabinowitz J, Davidov O. 2008b. The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data. Schizophrenia Bulletin 34(2): 286-291.
36. Spineli LM, Leucht S, Cipriani A, Higgins JP, Salanti G. 2013. The impact of trial characteristics on premature discontinuation of antipsychotics in schizophrenia. European Neuropsychopharmacology 23(9): 1010-1016.
37. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. 2001. Dropout rates in randomised antipsychotic drug trials. Psychopharmacology 155(3): 230-233.
38. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, Furukawa TA. 2011. Mirtazapine versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews (12): CD006528. doi: 10.1002/ 14651858.CD006528.pub2.
39. White IR, Higgins JP, Wood AM. 2008. Allowing for uncertainty due to missing data in meta-analysis--part 1: two-stage methods. Statistics in Medicine 27(5): 711-727.
40. Wood AM, White IR, Thompson SG. 2004. Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals. Clinical Trials 1(4): 368-376.